New York lawmakers won't pass a 340B drug program protection bill this session, disappointing hospitals and health centers ...
Select hospitals have refused to share data to prove they’re not double-dipping drug discounts, Lilly said. Hospitals, which ...
When hospitals overcharge insurers for drugs they bought at deep 340B discounts, taxpayers, employers, and insured patients ...
Eli Lilly moves to deny 340B discounts to hospitals refusing to submit claims data under its documentation policy, escalating ...
Three hospitals have sued CVS Health alleging the company redirected $250 million in savings from the 340B program. Mount Sinai Hospital, including St. Luke's-Roosevelt Hospital and Mount Sinai Beth ...
CVS Health (NYSE:CVS) is facing lawsuits from multiple health systems that allege the company diverted hundreds of millions ...
Eli Lilly and Company said Monday evening that it will soon end 340B discount pricing for some of the hospitals that have not ...
The past year has seen a great deal of controversy surrounding the 340B Drug Pricing Program, in which drug manufacturers make prescription drugs available to safety net healthcare providers at deeply ...
This appeal concerns Maine's effort to use state law to impose additional obligations on drug manufacturers who participate ...
As we enter into the final months of 2024, new developments in the administration of the 340B Drug Pricing Program signal that additional reform may be on the way. Although recent revisions to the ...
The Patient Protection and Affordable Care Act is expected to bring significant change to the healthcare industry, including the expansion of the Public Health Service Act Section 340B Program.
Critical decisions are pending before courts and legislators in 2023 that promise to shape the future of the 340B Drug Pricing Program (340B Program), which provides discounts on outpatient drugs for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results